Two-Year Follow-Up Results from KEYNOTE-045 Study in Urothelial Carcinoma
Joaquim Bellmunt, MD, PhD, a medical oncologist at the Bladder Cancer Center at Dana-Farber Cancer Institute, discusses the updated results of the phase III KEYNOTE-045 trial after 2 years of follow-up. These updated results confirmed the primary findings of the study, which compared pembrolizumab (Keytruda) with investigator's choice of chemotherapy in patients with recurrent, advanced urothelial carcinoma.
Joaquim Bellmunt, MD, PhD, a medical oncologist at the Bladder Cancer Center at Dana-Farber Cancer Institute, discusses the updated results of the phase III KEYNOTE-045 trial after 2 years of follow-up. These updated results confirmed the primary findings of the study, which compared pembrolizumab (Keytruda) with investigator's choice of chemotherapy in patients with recurrent, advanced urothelial carcinoma.
Pembrolizumab continued to show superior benefit over chemotherapy at 2 years of follow-up, and the hazard ratio for survival has improved since the original analysis to be 0.70, indicating a 30% reduction in the risk of death with the PD-1 inhibitor.
Responses observed thus far have been durable, and newer responses have occurred since the primary analysis. The median duration of response to treatment with pembrolizumab has not yet been reached versus 4.5 months with chemotherapy.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
